| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/19/2001 | US6248350 Antiinflammatory analgesic patch |
| 06/19/2001 | US6248320 Herpes simplex virus; genetic engineering |
| 06/19/2001 | CA2125964C Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists |
| 06/19/2001 | CA2013893C Tetrahydrobenz¬c,d|indole serotonin agonists |
| 06/14/2001 | WO2001042794A2 Method for identifying inhibitors of cytokinesis |
| 06/14/2001 | WO2001042784A2 Methods for screening compounds active on neurons |
| 06/14/2001 | WO2001042484A1 Il-6 like polynucleotide |
| 06/14/2001 | WO2001042471A2 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | WO2001042459A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 06/14/2001 | WO2001042421A2 Long-term cell culture compositions and genetically modified animals derived therefrom |
| 06/14/2001 | WO2001042306A2 Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042301A1 Interferon-alpha induced gene |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042265A2 N6 heterocyclic 8-modified adenosine derivatives |
| 06/14/2001 | WO2001042252A1 New aminopropylphosphinic acids |
| 06/14/2001 | WO2001042246A2 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| 06/14/2001 | WO2001042241A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | WO2001042238A1 Heterocyclic derivatives |
| 06/14/2001 | WO2001042225A2 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042216A2 Caspase inhibitors and uses thereof |
| 06/14/2001 | WO2001042215A1 4-pyridinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | WO2001042213A1 Urea compounds having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001042212A1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001042203A1 Cyclopentyl sulfonamide derivatives |
| 06/14/2001 | WO2001042193A1 β2-ADRENERGIC RECEPTOR AGONISTS |
| 06/14/2001 | WO2001042191A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/14/2001 | WO2001041807A2 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 06/14/2001 | WO2001041803A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-α AND CD95L IN A MEDICAMENT |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041782A2 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 06/14/2001 | WO2001041771A2 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 06/14/2001 | WO2001041769A2 Combination of cyamemazine and an atypical neuroleptic |
| 06/14/2001 | WO2001041768A2 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/14/2001 | WO2001041766A1 The combination of a serotonin reuptake inhibitor and irindalone |
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041756A2 Method and composition for treatment of ischemic neuronal reperfusion injury |
| 06/14/2001 | WO2001041752A2 Use of isoform specific inhibitors of cgmp-dependent protein kinase for treatment of pain |
| 06/14/2001 | WO2001041751A2 Phytoestrogens for treating als |
| 06/14/2001 | WO2001041750A2 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 06/14/2001 | WO2001041749A2 Combinations of sumatriptan or naratriptan with cyclooxygenase iiinhibitor |
| 06/14/2001 | WO2001041704A2 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | WO2001041701A2 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001027111A3 Bicyclic imidazo-3-yl-amine derivatives |
| 06/14/2001 | WO2001027101A3 Anhydrous salt |
| 06/14/2001 | WO2001017989A3 Heteroaryloxypropanolamines as beta3-adrenergic receptor agonists |
| 06/14/2001 | WO2001013904A3 Composition comprising a tramadol material and an anticonvulsant drug |
| 06/14/2001 | WO2001007022A3 Azetidine compounds in cns and eye diseases |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | WO2001000812A3 22012, a novel human carboxypeptidase |
| 06/14/2001 | WO2000068267A9 LOW-DOSE IL-1β-INDUCED PHOTORECEPTOR CELL RESCUE WITHOUT RETINAL DYSPLASIA |
| 06/14/2001 | WO2000064441A3 Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| 06/14/2001 | US20010003752 Crystalline form of 4- [ 5-methyl-3-phenylisoxazol-4-yl ] benzenesulfonamide |
| 06/14/2001 | US20010003749 Arylpiperazines having activity at the serotonin 1A receptor |
| 06/14/2001 | US20010003747 Useful in treating or in preventing melatoninergic disorders |
| 06/14/2001 | US20010003741 Aminoalcohol derivative and medicament comprising the same |
| 06/14/2001 | CA2733434A1 Caspase inhibitors and uses thereof |
| 06/14/2001 | CA2395039A1 Method for identifying inhibitors of cytokinesis |
| 06/14/2001 | CA2394917A1 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | CA2394303A1 Interferon-alpha induced gene |
| 06/14/2001 | CA2394060A1 Transmucosal administration of phosphodiesterase inhibitor for the treatment of erectile dysfunction |
| 06/14/2001 | CA2393779A1 Combination of compounds that inhibit the biological effects of tnf-.alpha. and cd95l in a medicament |
| 06/14/2001 | CA2393763A1 Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| 06/14/2001 | CA2393748A1 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 06/14/2001 | CA2393688A1 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393470A1 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 06/14/2001 | CA2393071A1 Long-term cell culture compositions and genetically modified animals derived therefrom |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392740A1 Il-6 like polynucleotides, polypeptides, and antibodies |
| 06/14/2001 | CA2392584A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | CA2392568A1 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | CA2392566A1 4-pyridinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | CA2384982A1 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | CA2361647A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/13/2001 | EP1107005A1 Method for identifying inhibitors of cytokinesis |
| 06/13/2001 | EP1107003A1 Methods for screening compounds active on neurons |
| 06/13/2001 | EP1106615A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106614A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106609A2 Aminoalcohol derivative and medicament comprising the same |
| 06/13/2001 | EP1106608A1 Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 06/13/2001 | EP1106210A2 Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
| 06/13/2001 | EP1106180A1 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/13/2001 | EP1106179A2 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 06/13/2001 | EP1105734A2 Homer interacting proteins |
| 06/13/2001 | EP1105728A1 Modulating multiple lineage kinase proteins |
| 06/13/2001 | EP1105481A2 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use |
| 06/13/2001 | EP1105478A1 Extracellular adhesive proteins, exadh1 and exadh2 |
| 06/13/2001 | EP1105464A1 Human mesencephalon cell lines and methods of use therefor |
| 06/13/2001 | EP1105462A1 Engraftable human neural stem cells |
| 06/13/2001 | EP1105459A1 Transgenic nonhuman mammal and uses thereof to identify compounds useful for improving long-term memory |
| 06/13/2001 | EP1105420A1 Cyclic prosaposin-derived peptides and uses thereof |